These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 10510891

  • 1. Prostate-specific antigen adjusted for the transition zone volume versus free-to-total prostate-specific antigen ratio in predicting prostate cancer.
    Moon DG, Cheon J, Kim JJ, Yoon DK, Koh SK.
    Int J Urol; 1999 Sep; 6(9):455-62. PubMed ID: 10510891
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F.
    Ann Clin Lab Sci; 2003 Sep; 33(3):320-3. PubMed ID: 12956448
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of prostate-specific antigen adjusted for transition zone volume versus prostate-specific antigen density in predicting prostate cancer by transrectal ultrasonography.
    Sung DJ, Cho SB, Kim YH, Oh YW, Lee NJ, Kim JH, Chung KB, Moon DG.
    J Ultrasound Med; 2004 May; 23(5):615-22. PubMed ID: 15154527
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [PSATZ (prostate specific antigen adjusted for the transition zone volume)].
    Maeda H, Okubo K, Arai Y.
    Nihon Rinsho; 1998 Aug; 56(8):2016-20. PubMed ID: 9750499
    [Abstract] [Full Text] [Related]

  • 11. Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer.
    Maeda H, Arai Y, Ishitoya S, Okubo K, Aoki Y, Okada T.
    J Urol; 1997 Dec; 158(6):2193-6. PubMed ID: 9366342
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels.
    Furuya Y, Ohta S, Sato N, Kotake T, Sugano I, Nagao K, Masai M.
    Anticancer Res; 2001 Dec; 21(2B):1317-20. PubMed ID: 11396206
    [Abstract] [Full Text] [Related]

  • 13. The influence of prostate volume on the prostate-specific antigen (PSA) level adjusted for the transition zone volume and free-to-total PSA ratio: a prospective study.
    Moon DG, Yu JW, Lee JG, Kim JJ, Koh SK, Cheon J.
    BJU Int; 2000 Oct; 86(6):670-4. PubMed ID: 11069374
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K, Nomi M, Egawa S, Morisue K, Takenaka A, Okamoto M, Ohori M, Fujii A.
    Cancer; 1997 May 15; 79(10):1969-76. PubMed ID: 9149025
    [Abstract] [Full Text] [Related]

  • 16. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
    Kubota Y, Kamei S, Nakano M, Ehara H, Deguchi T, Tanaka O.
    Int J Urol; 2008 Apr 15; 15(4):322-6; discussion 327. PubMed ID: 18380820
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men.
    Sheikh M, Al-Saeed O, Kehinde EO, Sinan T, Anim JT, Ali Y.
    Int Urol Nephrol; 2005 Apr 15; 37(4):721-6. PubMed ID: 16362587
    [Abstract] [Full Text] [Related]

  • 19. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml.
    Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ.
    J Urol; 2001 Jun 15; 165(6 Pt 1):1930-6. PubMed ID: 11371884
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.